Fulgent Genetics Inc (FLGT)
18.66
+0.15
(+0.81%)
USD |
NASDAQ |
Dec 26, 16:00
18.66
0.00 (0.00%)
After-Hours: 16:06
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 570.75M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -38.77% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.016 |
| Price to Book Value | 0.5013 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0026 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 90.91% |
Profile
| Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign. |
| URL | https://www.fulgentgenetics.com |
| Investor Relations URL | https://fulgentgenetics.gcs-web.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Feb. 28, 2025 (est.) |
| Last Earnings Release | Nov. 08, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign. |
| URL | https://www.fulgentgenetics.com |
| Investor Relations URL | https://fulgentgenetics.gcs-web.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Feb. 28, 2025 (est.) |
| Last Earnings Release | Nov. 08, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |